Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432 | Zendy

Patricia LoRusso | Zendy; Karthik Venkatakrishnan | Zendy; Ramesh K. Ramanathan | Zendy; John Sarantopoulos | Zendy; Daniel Mulkerin | Zendy; Stephen Shibata | Zendy; Anne Hamilton | Zendy; Afshin Dowlati | Zendy; Sridhar Mani | Zendy; Michelle A. Rudek | Zendy; Chris H. Takimoto | Zendy; Rachel Neuwirth | Zendy; Dixie-Lee Esseltine | Zendy; S. Percy Ivy | Zendy

Open Access

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Author(s) -

Patricia LoRusso,

Karthik Venkatakrishnan,

Ramesh K. Ramanathan,

John Sarantopoulos,

Daniel Mulkerin,

Stephen Shibata,

Anne Hamilton,

Afshin Dowlati,

Sridhar Mani,

Michelle A. Rudek,

Chris H. Takimoto,

Rachel Neuwirth,

Dixie-Lee Esseltine,

S. Percy Ivy

Publication year - 2012

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-11-2873

Subject(s) - bortezomib , medicine , pharmacokinetics , cmax , dosing , cancer , gastroenterology , liver function , adverse effect , toxicity , hepatic dysfunction , proteasome inhibitor , multiple myeloma

The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism. This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to inform dosing recommendations in these special populations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research